Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Baltimore, Maryland

Cancer surgery and procedure trials in Baltimore, MD

52 cancer surgery and procedure studies are recruiting participants at sites in Baltimore as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Baltimore at a glance

  • 52 studies are recruiting at a site in Baltimore.
  • By phase: Phase 1 (1), Phase 1/2 (4), Phase 2 (12), Phase 2/3 (1), Phase 3 (23), No phase (5), Observational (6). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (32), government (19), industry (1).
  • By research area: Lymphoma (16), Lung Cancer (12), Breast Cancer (9), Prostate Cancer (7), Pancreatic Cancer (5), Melanoma (3).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Baltimore

Basic details from each study's public record (the 30 most recently updated of 52). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT03606967 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT05564377 · updated
  3. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Greater Baltimore Medical Center · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT07391774 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Mercy Medical Center · Sinai Hospital of Baltimore
    Registry record
    NCT06058377 · updated
  5. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    MedStar Franklin Square Medical Center/Weinberg Cancer Institute · Mercy Medical Center · Sinai Hospital of Baltimore
    Registry record
    NCT05334069 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Lung cancer studies recruiting in Baltimore

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT06498635 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT06287775 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Greater Baltimore Medical Center · Johns Hopkins University/Sidney Kimmel Cancer Center · Kaiser Permanente-Woodlawn Medical Center
    Registry record
    NCT04267848 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT06096844 · updated
  5. Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
    Registry record
    NCT02984761 · updated
  6. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Kaiser Permanente-Woodlawn Medical Center
    Registry record
    NCT06031688 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Prostate cancer studies recruiting in Baltimore

  1. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT05691465 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT04423211 · updated
  3. Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

    • No phase
    • Ages 18 and older
    • Male participants
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT05792722 · updated
  4. Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Maryland Proton Treatment Center · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT07200830 · updated
  5. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Maryland Proton Treatment Center · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT05946213 · updated
  6. Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

    • Observational
    • Ages 18 and older
    • Male participants
    Sponsor
    University of Washington
    Study site
    Johns Hopkins University
    Registry record
    NCT04489719 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Melanoma studies recruiting in Baltimore

  1. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT05896839 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Baltimore, MD on ClinicalTrials.gov.

Lymphoma studies recruiting in Baltimore

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT06337318 · updated
  3. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore
    Registry record
    NCT04726241 · updated
  4. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT06724237 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT04269902 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT05675410 · updated
  8. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT07003295 · updated
  9. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT03150693 · updated
  10. Collection of Tissue Samples for Cancer Research

    • Observational
    • From 2 months
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University
    Registry record
    NCT00900198 · updated
  11. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore
    Registry record
    NCT06124157 · updated
  12. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT05633615 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Baltimore, MD on ClinicalTrials.gov.

Ask about studies near Baltimore

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call